Essex Bio-Technology (SEHK:1061) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

1061 Aperçu des actions

1061 analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	0/6
Performances passées	4/6
Santé financière	6/6
Dividendes	4/6

Récompenses

Le ratio cours/bénéfice ( 5 x) est inférieur au marché Hong Kong ( 9 x)

Les bénéfices ont augmenté de 22.1% au cours de l'année écoulée

Analyse des risques

Historique instable des dividendes

Essex Bio-Technology Limited Concurrents

TOT BIOPHARM International

SEHK:1875

HK$1.4b

Uni-Bio Science Group

SEHK:690

HK$339.0m

HBM Holdings

SEHK:2142

HK$864.6m

3SBio

SEHK:1530

HK$15.1b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Essex Bio-Technology
Historique des cours de bourse
Prix actuel de l'action	HK$2.40
Plus haut sur 52 semaines	HK$3.29
Plus bas sur 52 semaines	HK$1.96
Bêta	0.25
1Variation sur 1 mois	0.42%
Variation sur 3 mois	-4.38%
Variation sur 1 an	-25.00%
3Variation sur 3 ans	-62.50%
Variation sur 5 ans	-51.52%
Évolution depuis l'introduction en bourse	142.42%

Nouvelles et mises à jour récentes

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

May 06

Recent updates

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

May 02

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Mar 30

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Jun 29

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Mar 31

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Mar 13

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Feb 15

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

Jan 25

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Jan 04

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 13

Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

Nov 23

Rendement pour les actionnaires

	1061	HK Biotechs	HK Marché
7D	0%	3.0%	1.3%
1Y	-25.0%	-24.2%	4.2%

Rendement vs Industrie: 1061 correspondait au secteur Hong Kong Biotechs qui a rapporté -24.2 % au cours de l'année écoulée.

Rendement vs marché: 1061 a sous-performé le marché Hong Kong qui a rapporté 6.2 % au cours de l'année écoulée.

Volatilité des prix

Is 1061's price volatile compared to industry and market?
1061 volatility
1061 Average Weekly Movement	3.9%
Biotechs Industry Average Movement	7.0%
Market Average Movement	6.3%
10% most volatile stocks in HK Market	13.2%
10% least volatile stocks in HK Market	3.4%

Cours de l'action stable: 1061 n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de 1061 ( 4% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1990	1,481	Haizhou Fang	www.essexbio.com

Essex Bio-Technology Limited, une société holding d'investissement, développe, fabrique, distribue et vend des produits biopharmaceutiques en République populaire de Chine, à Hong Kong et au niveau international. La société exerce ses activités dans les secteurs de l'ophtalmologie et de la chirurgie. Elle recherche et développe des produits thérapeutiques à base de facteur de croissance des fibroblastes pour le traitement de la prolifération, de la différenciation et de la migration cellulaires.

Essex Bio-Technology Limited Résumé des fondamentaux

Comment les bénéfices et les revenus de Essex Bio-Technology se comparent-ils à sa capitalisation boursière ?
1061 statistiques fondamentales
Capitalisation boursière	HK$1.36b
Bénéfices(TTM)	HK$275.26m
Recettes(TTM)	HK$1.71b

4.9x

Ratio P/E

0.8x

Ratio P/S

Le site 1061 est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
1061 compte de résultat (TTM)
Recettes	HK$1.71b
Coût des recettes	HK$167.26m
Marge brute	HK$1.54b
Autres dépenses	HK$1.26b
Les revenus	HK$275.26m

Derniers bénéfices déclarés

Dec 31, 2023

Prochaine date de publication des résultats

Aug 26, 2024

Résultat par action (EPS)	0.49
Marge brute	90.20%
Marge bénéficiaire nette	16.13%
Ratio dettes/capitaux propres	14.1%

Quelles ont été les performances à long terme de 1061?

Voir les performances historiques et les comparaisons

Dividendes

3.8%

Rendement actuel des dividendes

19%

Ratio de distribution

1061 Aperçu des actions

Récompenses

Analyse des risques

Essex Bio-Technology Limited Concurrents

SEHK:1875

HK$1.4b

SEHK:690

HK$339.0m

SEHK:2142

HK$864.6m

SEHK:1530

HK$15.1b

Historique des prix et performances

Nouvelles et mises à jour récentes

Essex Bio-Technology Limited to Report First Half, 2024 Results on Aug 26, 2024

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.045 per share

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

Now 21% overvalued

Now 22% overvalued

Recent updates

Essex Bio-Technology Limited to Report First Half, 2024 Results on Aug 26, 2024

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.045 per share

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

Now 21% overvalued

Now 22% overvalued

Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024

Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Essex Bio-Technology Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Financial data availability

Essex Bio-Technology Limited to Report Fiscal Year 2023 Results on Mar 18, 2024

Investor sentiment deteriorates as stock falls 16%

Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Upcoming dividend of HK$0.045 per share at 2.0% yield

First half 2023 earnings released: EPS: HK$0.30 (vs HK$0.24 in 1H 2022)

Essex Bio-Technology Limited to Report First Half, 2023 Results on Aug 16, 2023

Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative (Wet) Age-Related Macular Degeneration

Less than half of directors are independent

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.025 per share at 1.8% yield

Now 21% undervalued after recent price drop

Essex Bio-Technology Limited Completes First Patient First Dose in the United States in an International Multi-Centre Phase 3 Clinical Study

Essex Bio-Technology Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Price target decreased to HK$6.00

Less than half of directors are independent

Consensus revenue estimates fall by 18%

Upcoming dividend of HK$0.04 per share

Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

First half 2022 earnings released: EPS: HK$0.24 (vs HK$0.28 in 1H 2021)

Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on September 21, 2022

Essex Bio-Technology Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021

Price target increased to HK$7.00

Less than half of directors are independent

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.04 per share

First half 2021 earnings released: EPS HK$0.28 (vs HK$0.085 in 1H 2020)

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021 at the Annual General Meeting held on May 12, 2021

Upcoming dividend of HK$0.05 per share

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Essex Bio-Technology Limited Announces Dividend for the Year Ended December 31, 2020, Payable on 1 June 2021

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Essex Bio-Technology Limited, Annual General Meeting, May 12, 2021

Full year 2020 earnings released: EPS HK$0.38 (vs HK$0.52 in FY 2019)

Essex Bio-Technology Limited to Report Fiscal Year 2020 Results on Mar 12, 2021

Investor sentiment improved over the past week

Essex Bio-Technology Limited Announces Positive Outcome of U.S. FDA Second Phase 3 Clinical Trial in Dry Eye Disease

New 90-day high: HK$4.85

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?